We documented that the delivery of AEG-1 siRNA using a hepatocyte-targeted nanoparticle could effectively protect from HFD-induced NASH and inhibit orthotopic human HCC xenografts [302,305]. This evidence concerns the gene MTDH and metabolic dysfunction-associated steatohepatitis.